From: Primary resistance to first-generation EGFR-TKIs induced by MDM2 amplification in NSCLC
Patient 1 | Patient 2 | Patient 3 | Patient 4 | |
---|---|---|---|---|
Age | 62 | 60 | 59 | 67 |
Gender | male | female | female | male |
Race | Asian | Asian | Asian | Asian |
TNM stage | IV | IV | IV | IIIB |
Pathology | Moderately differentiated adenocarcinoma | Invasive adenocarcinoma | Poorly differentiated adenocarcinoma | Invasive adenocarcinoma |
EGFR-TKIs | Gefitinib | Gefitinib | Gefitinib | Gefitinib |
Regimen | 250 mg, qd | 250 mg, qd | 250 mg, qd | 250 mg, qd |
PFS (months) | 5.2 | 6.9 | 8.1 | 5.1 |
Genomic alterations | EGFR Exon 21 L858R MDM2 Amplification TP53 D208G ERBB4 L770V BLM D997N | EGFR Exon 19 Deletion MDM2 Amplification CDK4 Amplification ARID1B Q1312K NKX2–1 G115S PTCH1 G1136 RET R475W | EGFR Exon 19 Deletion MDM2 Amplification EGFR Amplification CDK4 Amplification CTIF R77L APC L1564 | EGFR Exon 21 L858R MDM2 Amplification FLT3 P336T FYN L411M FANCL M89I NCOR1 P347T |